China National Biotec Group
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From China National Biotec Group
Plus deals involving OliPass/Vanda, Simcere/Almirall, Sinopharm/Merck & Co., Jiuzhou/Sandoz, Zai Lab/Seagen, Sciwind/SynderK, Hansoh/KiOmed.
China's CSPC Pharmaceutical Group surprises by announcing investigator-initiated trial results for SYS6006, its mRNA COVID-19 vaccine candidate against the Omicron variant.
While two Chinese companies gained domestic approvals for their recombinant protein and adenovirus-based COVID-19 shots as heterologous boosters in February, these currently only account for roughly 21% of all booster shots, showing the continued predominance of inactivated virus-based technology in the country.
CanSino and Zhifei have received the regulatory green light for their respective COVID-19 booster shots in China and an estimated $1.3bn vaccine market is now up for grabs. Domestic contenders are set to elbow each other in the sector with a range of viral vector, recombinant protein and mRNA-based jabs.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.